Drug
Cimlanod clinical trials
Also written BMS-986231.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
10 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2014 | 2 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
Studies
Open first, then newest update. How each study uses cimlanod is read from its arms, and is right about nine times in ten.
Testing it · 10
- An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop DiureticCompletedPhase 2Bristol-Myers SquibbNCT03730961Written as BMS-986231
- Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart FailureCompletedPhase 2Bristol-Myers SquibbNCT03016325Written as HNO Donor
- An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver FunctionCompletedPhase 1Bristol-Myers SquibbNCT03515980Written as BMS-986231
- A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic FunctionCompletedPhase 2Bristol-Myers SquibbNCT03357731Written as HNO Donor
- A Pharmacokinetics, Safety and Tolerability Study of Multiple Formulations of BMS-986231 in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT03891108Written as BMS-986231 Formulation A
- A Study of Experimental Medication BMS-986231 in Patients With Different Levels of Kidney FunctionCompletedPhase 1Bristol-Myers SquibbNCT03332186Written as BMS-986231
- A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart FailureCompletedPhase 2Bristol-Myers SquibbNCT02157506Written as CXL-1427
- Pharmacokinetics and Metabolism of [14C] BMS-986231 in Healthy Male ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT03210909Written as BMS-986231
- Study With Healthy Japanese and Non-Asian Participants With BMS-986231CompletedPhase 1Bristol-Myers SquibbNCT02932969Written as BMS-986231
- A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy VolunteersCompletedPhase 1Bristol-Myers SquibbNCT02819271Written as CXL-1427 Ascending Dose
Codes
What other systems call cimlanod · ClinicalTrials.gg INT014537
- UNII (FDA) 2US4FK1EPVCIMLANODConfirmed FDA, Wikidata
- Wikidata Q28457133cimlanodConfirmed FDA, Wikidata
- NCI Thesaurus C166594CimlanodOne source FDA
- DrugBank DB14983One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 2US4FK1EPV | CIMLANOD | Confirmed FDA, Wikidata |
| Wikidata | Q28457133 | cimlanod | Confirmed FDA, Wikidata |
| NCI Thesaurus | C166594 | Cimlanod | One source FDA |
| DrugBank | DB14983 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.